(IMVT) Immunovant - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 7.301m USD | Total Return: 136.9% in 12m

Monoclonal Antibodies, Immunology Therapeutics
Total Rating 35
Safety 26
Buy Signal 0.55
Biotechnology
Industry Rotation: -8.2
Market Cap: 7.30B
Avg Turnover: 35.5M
Risk 3d forecast
Volatility87.6%
VaR 5th Pctl13.6%
VaR vs Median-5.61%
Reward TTM
Sharpe Ratio1.61
Rel. Str. IBD93
Rel. Str. Peer Group79.8
Character TTM
Beta1.180
Beta Downside1.024
Hurst Exponent0.418
Drawdowns 3y
Max DD69.88%
CAGR/Max DD0.25
CAGR/Mean DD0.48

Warnings

Share dilution 23.5% YoY

Beneish M-Score 0.85 > -1.5 - likely earnings manipulation

Altman Z'' -15.00 < 1.0 - financial distress zone

Tailwinds

Leader, Tailwind, Pullback 52w

Description: IMVT Immunovant

Immunovant, Inc. is a clinical-stage biotechnology company focused on developing targeted monoclonal antibody therapies for autoimmune diseases. Its primary candidates, IMVT-1402 and batoclimab, are designed to inhibit the neonatal Fc receptor (FcRn), a mechanism intended to reduce pathogenic IgG antibodies across multiple indications including Graves disease, myasthenia gravis, and thyroid eye disease.

Operating within the immunology sector, the company utilizes a hub-and-spoke business model as a subsidiary of Roivant Sciences Ltd. This structure allows the firm to focus resources on specific therapeutic assets while leveraging centralized infrastructure for clinical development. The FcRn inhibitor market is characterized by high barriers to entry due to complex protein engineering requirements and intensive regulatory approval processes for chronic treatments.

Investors may find it useful to examine ValueRay for further data on the companys competitive positioning.

Founded in 2018 and headquartered in Durham, North Carolina, Immunovant continues to advance its pipeline through various stages of clinical trials. The companys success depends on the clinical efficacy of its subcutaneous delivery methods, which aim to provide a more patient-friendly alternative to traditional intravenous infusions.

Headlines to Watch Out For
  • Clinical trial results for IMVT-1402 determine competitive advantage in FcRn inhibitor market
  • Regulatory approval timelines for batoclimab dictate path to initial commercial revenue
  • Potential acquisition by parent Roivant Sciences influences long-term equity valuation
  • Expansion of clinical pipeline into multi-indication autoimmune treatments drives investor sentiment
  • Competition from established pharmaceutical players impacts projected market share for lead assets
Piotroski VR‑10 (Strict) 0.0
Net Income: -464.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.40 > 0.02 and ΔFCF/TA 37.16 > 1.0
NWC/Revenue: 610k% < 20% (prev 22.9k%; Δ 587k% < -1%)
CFO/TA -0.40 > 3% & CFO -422.9m > Net Income -464.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 15.74 > 1.5 & < 3
Outstanding Shares: last quarter (181.5m) vs 12m ago 23.54% < -2%
Gross Margin: -145.6% > 18% (prev 0.78%; Δ -14.6k% > 0.5%)
Asset Turnover: 0.02% > 50% (prev 0.36%; Δ -0.33% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -15.00
A: 0.93 (Total Current Assets 1.04b - Total Current Liabilities 66.3m) / Total Assets 1.05b
B: -1.52 (Retained Earnings -1.60b / Total Assets 1.05b)
C: -0.65 (EBIT TTM -481.9m / Avg Total Assets 736.7m)
D: -24.09 (Book Value of Equity -1.60b / Total Liabilities 66.3m)
Altman-Z'' Score: -28.55 = D
Beneish M 0.85
DSRI: 6.93 (Receivables 1.64m/2.22m, Revenue 160k/1.50m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.47 (AQ_t 0.01 / AQ_t-1 0.02)
SGI: 0.11 (Revenue 160k / 1.50m)
TATA: -0.04 (NI -464.2m - CFO -422.9m) / TA 1.05b)
Beneish M-Score: 0.85 (Cap -4..+1) = D
What is the price of IMVT shares? As of May 22, 2026, the stock is trading at USD 34.13 with a total of 4,542,746 shares traded.
Over the past week, the price has changed by +17.85%, over one month by +20.69%, over three months by +25.48% and over the past year by +136.85%.
Is IMVT a buy, sell or hold? Immunovant has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy IMVT.
  • StrongBuy: 10
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the IMVT price?
Analysts Target Price 41.3 21%
Immunovant (IMVT) - Fundamental Data Overview as of 22 May 2026
P/B = 8.563
Revenue TTM = 160k USD
EBIT TTM = -481.9m USD
EBITDA TTM = -481.5m USD
 Long Term Debt = unknown (none)
 Short Term Debt = 72.0k USD (from shortTermDebt, last fiscal year)
Debt = 72.0k USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -994.5m USD (recalculated: Debt 72.0k - CCE 994.5m)
Enterprise Value = 6.31b USD (7.30b + Debt 72.0k - CCE 994.5m)
 Interest Coverage Ratio = unknown (Ebit TTM -481.9m / Interest Expense TTM 0.0)
 EV/FCF = -14.91x (Enterprise Value 6.31b / FCF TTM -423.1m)
FCF Yield = -6.71% (FCF TTM -423.1m / Enterprise Value 6.31b)
 FCF Margin = -264k% (FCF TTM -423.1m / Revenue TTM 160k)
 Net Margin = -290k% (Net Income TTM -464.2m / Revenue TTM 160k)
 Gross Margin = -145.6% ((Revenue TTM 160k - Cost of Revenue TTM 393k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 5.99 (Enterprise Value 6.31b / Total Assets 1.05b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 72.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -380.7m (EBIT -481.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.74 (Total Current Assets 1.04b / Total Current Liabilities 66.3m)
Debt / Equity = 0.00 (Debt 72.0k / totalStockholderEquity, last quarter 986.1m)
 Debt / EBITDA = 2.07 (negative EBITDA) (Net Debt -994.5m / EBITDA -481.5m)
 Debt / FCF = 2.35 (negative FCF - burning cash) (Net Debt -994.5m / FCF TTM -423.1m)
 Total Stockholder Equity = 705.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.01% (Net Income -464.2m / Total Assets 1.05b)
RoE = -65.80% (Net Income TTM -464.2m / Total Stockholder Equity 705.5m)
RoCE = -48.87% (EBIT -481.9m / Capital Employed (Total Assets 1.05b - Current Liab 66.3m))
 RoIC = -53.96% (negative operating profit) (NOPAT -380.7m / Invested Capital 705.5m)
 WACC = 10.13% (E(7.30b)/V(7.30b) * Re(10.13%) + D(72.0k)/V(7.30b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 15.54%
 [DCF] Fair Price = unknown (Cash Flow -423.1m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.44 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.62 | Chg30d=+4.43% | Revisions=+33% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.63 | Chg30d=+5.11% | Revisions=+33% | Analysts=11
EPS current Year (2027-03-31): EPS=-2.58 | Chg30d=-0.35% | Revisions=+50% | GrowthEPS=-4.7% | GrowthRev=+0.0%
EPS next Year (2028-03-31): EPS=-2.38 | Chg30d=-9.11% | Revisions=+33% | GrowthEPS=+7.8% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +50%